



July 26, 2025

The General Manager  
Corporate Relations Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001  
Scrip Code: 500770

The Manager  
National Stock Exchange of India Ltd.  
Exchange Plaza  
Bandra-Kurla Complex  
Bandra (E)  
Mumbai – 400 051  
Symbol: TATACHEM

Dear Sir/Madam,

**Sub: Newspaper Advertisement - Unaudited Consolidated and Audited Standalone Financial Results for the first quarter ended June 30, 2025**

The Board of Directors at their Meeting held on Friday, July 25, 2025, *inter alia*, approved the Unaudited Consolidated and Audited Standalone Financial Results of the Company for the quarter ended June 30, 2025.

The said financial results were published in the following newspapers on July 26, 2025:

- i. Business Standard (English)
- ii. The Free Press Journal (English)
- iii. Navshakti (Marathi)

A copy of the results published is attached herewith. These are also being made available on the website of the Company at [www.tatachemicals.com](http://www.tatachemicals.com).

You are requested to take the same on record.

Thanking you,



**Yours faithfully,  
For Tata Chemicals Limited**


**Rajiv Chandan  
Chief General Counsel  
& Company Secretary**

Encl.: a/a

**TATA CHEMICALS LIMITED**

Bombay House 24 Homi Mody Street Fort Mumbai 400 001  
Tel 91 22 6665 8282 Fax 91 22 6665 8143/44 [www.tatachemicals.com](http://www.tatachemicals.com)  
CIN : L24239MH1939PLC002893

 <b>SOLARA</b> Active Pharma Sciences		<b>SOLARA ACTIVE PHARMA SCIENCES LIMITED</b> <b>CIN: L24230MH2017PLC291636</b> <b>Regd. Office:</b> 9th Floor, "Cyber One", Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 <b>Tel:</b> +91-22-2789 2924 <b>Corporate Office:</b> TICEL BIO PARK, 6th floor Module No. 601, 602, 603, Phase II - CSIR Road, Taramani, Chennai, Tamil Nadu - 600113. <b>Tel:</b> +91 44 4344 6700   <b>Fax:</b> +91 44 47406190   <b>E-mail:</b> investors@solara.co.in, www.solara.co.in			
<b>STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025</b> (Rs. in Crores except per share data)					
Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous Financial Year ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		UNAUDITED	(Refer Note 5)	UNAUDITED	AUDITED
<b>Continuing operations:</b>					
1	Total income from operations	319.15	273.01	363.49	1,283.76
2	Net Profit for the period before tax (before exceptional items)	10.52	(2.10)	(13.46)	0.54
3	Net Profit for the period before tax (after exceptional items)	10.52	(2.10)	(13.46)	0.54
4	Net Profit for the period after tax	10.52	(2.10)	(13.46)	0.54
5	Other Comprehensive Income for the period	(0.01)	(0.62)	(0.01)	0.98
6	Total Comprehensive Income for the period (4 + 5)	10.51	(2.72)	(13.47)	1.52
7	Equity Share Capital	44.34	40.25	40.21	40.25
8	Other Equity				1,053.99
9	Earnings Per Share (of Rs. 10/- each) (for continuing operations) -				
	Basic (Rs.)	2.46	(0.93)	(3.50)	0.14
	Diluted (Rs.)	2.46	(0.93)	(3.50)	0.14
<b>Notes:</b>					
1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the National Stock Exchange of India Limited ( <a href="http://www.nseindia.com">www.nseindia.com</a> ), BSE Limited ( <a href="http://www.bseindia.com">www.bseindia.com</a> ) and at the Company's website ( <a href="http://www.solara.co.in">www.solara.co.in</a> )					
2 The above consolidated financial results of Solara Active Pharma Sciences Limited ("the Parent" or the Company" and its subsidiaries (together referred to as "the group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on July 25, 2025. The results for the quarter ended June 30, 2025 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have expressed an unmodified conclusion in respect of limited review for the quarter ended June 30, 2025.					
3 The Parent, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 partly paid equity shares of face value of Rs. 10/- each at a price of Rs. 375 per Equity share (including Share premium of Rs. 365 per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Parent on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record date i.e May 15, 2024. Rights issue has been done in accordance with Section 62(1)(a) of the Companies Act and other applicable laws. The Parent has allotted 1,19,98,755 Nos. of partly paid up equity shares on June 19, 2024. On March 26, 2025, the Company, approved the Rights Issue First Call of Rs. 131.25 per Rights Share (Rs. 3.50 face value and Rs. 127.75 Share premium) for 1,19,98,755 partly paid Rights Shares, as per the Letter of Offer dated May 09, 2024. The First Call payment window was open from April 16, 2025 to April 30, 2025. The Rights Issue Subcommittee on May 06, 2025, took note of receipt of First call money amounting Rs.149.49 Crores and approved conversion of 1,13,89,767 partly paid shares of Rs. 3.5 per share to partly paid of Rs. 7 per share. Out of net proceeds from First Call money, Rs. 115.00 crores is used against repayment of borrowings, Rs.23.27 crores towards general corporate purposes in line with terms of utilization mentioned in letter of offer.					
4 The Board of Directors of the Parent at its meeting held on January 24, 2025 had discussed a proposal to explore 'demerger of the CRAMS and Polymers business into an independent listed entity' and granted in-principle approval for the same. Pursuant to this, the Parent incorporated a wholly owned subsidiary, Synthix Global Pharma Solutions Limited, on April 29, 2025.					
5 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and year to date figures up to third quarter of the financial year then ended as disclosed in the financial results for the year ended March 31, 2025.					
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> <b>Place :</b> Bengaluru  <b>Date :</b> July 25, 2025         </div> <div style="text-align: center;">  </div> <div style="text-align: right;"> <b>For and on behalf of board</b>  <b>Sd/-</b>  <b>Sandeep Shashikantha Rao</b>  <b>MD &amp; CEO</b>  <b>DIN: 10838251</b> </div> </div>					

<div style="text-align: center;">   <b>Extracts of Statement of Consolidated Financial Results</b>  <b>for the quarter ended 30 June, 2025</b> </div>				
(₹ in crore)				
Particulars	Quarter ended 30 June, 2025 (Unaudited)	Quarter ended 31 March, 2025 (Audited)	Quarter ended 30 June, 2024 (Unaudited)	Year ended 31 March, 2025 (Audited)
	Not annualised			Annualised
1. Revenue from continuing operations	3,719	3,509	3,789	14,887
2. Profit/(loss) from continuing operations before exceptional items, share of profit/(loss) of joint ventures and associate and tax	318	(61)	215	492
3. Profit/(loss) from continuing operations after exceptional items, before share of profit/(loss) of joint ventures and associate and tax	318	(116)	215	367
4. Profit/(loss) from continuing operations before tax	360	(92)	269	521
5. Profit/(loss) from continuing operations after tax	316	(67)	175	354
6. Profit/(loss) from discontinued operations after tax	-	18	15	33
7. Profit/(loss) for the period (5 + 6)	316	(49)	190	387
8. Total comprehensive income for the period	1,037	(79)	(178)	(114)
9. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255
10. Other equity and Non-controlling interests				22,246
11. Securities premium account	1,259	1,259	1,259	1,259
12. Net worth	23,215	22,501	22,514	22,501
13. Outstanding debt	7,126	7,072	6,376	7,072
14. Earnings per share				
- Basic and Diluted (for continuing operations) in ₹	9.89	(2.90)	5.30	7.93
- Basic and Diluted (for discontinued operations) in ₹	-	0.71	0.59	1.30
- Basic and Diluted (for continuing and discontinued operations) in ₹	9.89	(2.19)	5.89	9.23
15. Debt equity ratio (no. of times)	0.31	0.31	0.28	0.31
16. Debt service coverage ratio (no. of times)	3.88	2.84	3.35	2.71
17. Interest service coverage ratio (no. of times)	4.41	2.39	4.32	3.47

Extracts of Statement of Standalone Audited Financial Results for the quarter ended 30 June, 2025				
(₹ in crore)				
Particulars	Quarter ended 30 June, 2025	Quarter ended 31 March, 2025	Quarter ended 30 June, 2024	Year ended 31 March, 2025
	Not annualised			Annualised
1. Revenue from continuing operations	1,169	1,219	1,047	4,441
2. Profit from continuing operations before tax	332	102	322	624
3. Profit from continuing operations after tax	307	97	256	524
4. Profit from discontinued operations after tax	-	18	15	33
5. Profit for the period (3 + 4)	307	115	271	557
6. Total comprehensive income for the period	1,060	(18)	(120)	(149)
7. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255
8. Other equity				17,939
9. Securities premium account	1,258	1,258	1,258	1,258
10. Net worth	18,974	18,194	18,223	18,194
11. Outstanding debt	1,979	2,261	574	2,261
12. Earnings per share				
- Basic and Diluted (for continuing operations) in ₹	12.05	3.80	10.05	20.57
- Basic and Diluted (for discontinued operations) in ₹	-	0.71	0.59	1.30
- Basic and Diluted (for continuing and discontinued operations) in ₹	12.05	4.51	10.64	21.87
13. Debt equity ratio (no. of times)	0.10	0.12	0.03	0.12
14. Debt service coverage ratio (no. of times)	19.29	5.23	27.20	13.86
15. Interest service coverage ratio (no. of times)	5.40	4.69	18.08	5.68

**Notes:**

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 25 July, 2025.
- The above is an extract of the detailed format of the Unaudited Consolidated and Audited Standalone financial results for the quarter ended 30 June, 2025 filed with the Stock Exchanges under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Consolidated and Audited Standalone financial results for the quarter ended 30 June, 2025 is available on the Stock Exchange websites ([www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)) and on the Company's website ([www.tatachemicals.com](http://www.tatachemicals.com)). The same can be accessed by scanning the QR code provided below.

For and on behalf of the Board of

**TATA CHEMICALS LIMITED**

**R. Mukundan**  
Managing Director and CEO







